Dr. Gould on the Implications of the NELSON Trial in Lung Cancer

Video

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

Findings from the NELSON trial showed a 24% reduction in lung cancer mortality in high-risk patients who underwent volume CT screening. Unlike the National Lung Screening Trial (NLST), investigators did not find an associated reduction in all-cause mortality; however, that may be due to the smaller size of the trial, says Gould. In both studies, screening carried a risk of a false-positive test result. In the NLST, about 40% of patients had at least 1 positive test result after 3 rounds of screening and over 95% of those positive findings were false positives. Now that the benefit of screening has been demonstrated, investigators are working to reduce the false-positive rate or find ways to distinguish between a true positive and false-positive result, says Gould.

Notably, in the NELSON trial, investigators used nodule volume and volume-doubling time to calculate the size of the tumor. Anyone who had a nodule of a certain size came back 3 months later for a follow-up scan and, if the nodule was still present, it was remeasured. The comparison between the size of the nodule on the baseline screening test and the size of the nodule on the follow-up tests demonstrated that benign growths were mostly scar tissue, concludes Gould.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute